Pretransplantation Dermatologic Screening and Prophylaxis
In the United States, more than 29,000 patients receive solid organ transplants annually, and the number worldwide is many times higher. Organ transplantation offers increased quality of life and prolongs survival for hundreds of thousands of patients with debilitating end-stage organ disease. This “gift of life” is possible with potent systemic immunosuppression, which prevents post-transplant immunological rejection of the donor allograft. However, the immunosuppression is not specific for prevention of allograft rejection, and many adverse effects accrue with prolonged survival. Primary among these is skin cancer, the most common malignancy of solid organ transplant recipients.
Unable to display preview. Download preview PDF.
- 4.European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.2. Cancer risk after renal transplantation. Skin cancers: prevention and treatment. Nephrol Dial Transplant 2002; 17(Suppl 4):31–6.Google Scholar
- 16.Wulf HC, Pavel S, Stender I, et al. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Dermatol Venereol 2006; 86:25–8.Google Scholar
- 24.Clowers-Webb HE, Christenson LJ, Phillips PK, et al. Educational outcomes regarding skin cancer in organ transplant recipients: Randomized intervention of intensive vs. standard education. Arch Dermatol 2006; 142:712–8.Google Scholar
- 26.AT-RISC.org [homepage on the Internet]. After Transplantation–Reduce Incidence of Skin Cancer. Available from: http://www.at-risc.org/ Accessed: October 1, 2006.